Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2442469 | 0.87 | AAK1 (0.34) | HTR2AHSD11B1SLC6A4ADRA1DKCNH2 | |
| SCHEMBL2442353 | 0.86 | XIAP (0.41) | — | |
| SCHEMBL2445839 | 0.82 | XIAP (0.32) | HTR2ASLC6A4KCNH2DRD2HTR7 | |
| SCHEMBL12299610 | 0.80 | DPP9 (0.41) | DPP9DPP4DPP8HTR2AHSD11B1 | |
| SCHEMBL1925030 | 0.80 | DPP9 (0.41) | DPP9DPP4DPP8HTR2AHSD11B1 | |
| SCHEMBL2446124 | 0.78 | CTSL (0.42) | — | |
| SCHEMBL12299761 | 0.75 | DPP9 (0.45) | DPP9DPP4DPP8HTR2AHSD11B1 | |
| SCHEMBL2447641 | 0.75 | DPP9 (0.45) | DPP9DPP4DPP8HTR2AHSD11B1 | |
| SCHEMBL2440601 | 0.73 | TGM2 (0.33) | DPP8HTR2ASLC6A4KCNH2DRD2 | |
| SCHEMBL2442069 | 0.73 | SCN9A (0.33) | HTR2ASLC6A4ADRA1DKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| EP-2328412-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010033531-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | DPP9 23/4885DPP4 34/4885DPP8 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.